Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus
(2025)
Journal Article
Wray, R., Paverd, H., Machado, I., Barbieri, J., Easita, F., Edwards, A. R., Gallagher, F. A., Mendichovszky, I. A., Mitchell, T. J., De La Roche, M., Shields, J. D., Ursprung, S., Wallis, L., Warren, A. Y., Welsh, S. J., Crispin-Ortuzar, M., Stewart, G. D., & Jones, J. O. (2025). Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus. Nature Communications, 16, Article 3870
Venous tumour thrombus (VTT), where the primary tumour invades the renal vein and inferior vena cava, affects 10-15% of renal cell carcinoma (RCC) patients. Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes. The NAXI... Read More about Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus.